Sugi Predict

Sugi Predict / Compounds / SCHEMBL2656808

SCHEMBL2656808

SCHEMBL2656808

[CH](C1=CCCC1)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.35
▸ F3 P13726 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.34
▸ HTT P42858 1/20 0.34
▸ TSHR P16473 1/20 0.32
▸ MAOB P27338 1/20 0.32
▸ CYP2A6 P11509 1/20 0.32
▸ LMNA P02545 3/20 0.32
▸ HPGD P15428 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ FGF23 Q9GZV9 1/20 0.31
▸ GRM5 P41594 1/20 0.30
▸ MGAM O43451 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ SI P14410 1/20 0.30
▸ MGAM2 Q2M2H8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646883 0.94 HPGD (0.37) CYP1A2F3ALDH1A1HTTTSHR
SCHEMBL2659581 0.84 CYP1A2 (0.37) CYP1A2F3ALDH1A1HTTTSHR
SCHEMBL6047849 0.75 NPC1 (0.42) MAOBLMNAHPGDNPC1RAB9A
SCHEMBL6470539 0.72 KMT2A (0.36) CYP1A2ALDH1A1MAOBNPC1RAB9A
SCHEMBL7609745 0.71 KDM1A (0.34) —
SCHEMBL13837633 0.67 CYP1A2 (0.31) CYP1A2ALDH1A1TSHRMAOBCYP2A6
SCHEMBL1302 0.66 ALDH1A1 (0.53) CYP1A2F3ALDH1A1TSHRMAOB
SCHEMBL75132 0.64 — —
SCHEMBL73139 0.64 — —
SCHEMBL262241 0.64 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 — — EP claimed
CN-101610995-A Novel glucagon receptor antagonists METABASIS THERAPEUTICS INC (US) 2009-12-23 — — CN claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 — — EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO claimed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 — — US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 — — US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 — — EP disclosed
CN-107669669-A novel glucagon receptor antagonist 症变治疗公司 2018-02-09 — — CN disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
CN-101610995-B Glucagon receptor antagonists 症变治疗公司 2017-08-08 — — CN disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 — — US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 — — US disclosed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-8710236-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2014-04-29 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
CN-101610995-A Novel glucagon receptor antagonists METABASIS THERAPEUTICS INC (US) 2009-12-23 — — CN disclosed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 — — EP disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 CYP1A2 2307/4885F3 1015/4885ALDH1A1 4644/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 CYP1A2 2054/4885F3 892/4885ALDH1A1 4662/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 CYP1A2 2272/4885F3 1014/4885ALDH1A1 4642/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 CYP1A2 2272/4885F3 1014/4885ALDH1A1 4642/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 CYP1A2 2272/4885F3 1014/4885ALDH1A1 4642/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 CYP1A2 2016/4885F3 884/4885ALDH1A1 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.